Episodes
-
HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.
These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.
In this episode of HOPA Now, Dr. Lisa Holle discusses genitourinary cancer clinical pearls, including bladder cancer survival benefit options such as split dose treatments, primary treatment options for early and late-stage renal cancers, bone modifying agent recommendations for patients with bone metastases and management for asymptomatic patients.
In this episode you will learn:
Genitourinary Cancers: Top 10 Clinical Pearls
Bladder cancer survival benefit options, including split-dose treatments The relationship between vitamin B12 deficiencies and bladder resections The primary treatment of early-stage renal cancer with one exception Criteria for the treatment of stage 4 renal cancer Bone-modifying agent recommendations for renal cancer Management for asymptomatic, early-stage prostate cancer patients Relugolix as an ADT option in some prostate cancers Considerations for treatment of relapsed or refractory prostate cancer patients Dosing of bone-modifying agents used in prostate cancer patients Radiation therapy recommendations based on cancer stages Preferred chemotherapy for nonseminoma and seminoma Bleomycin pulmonary toxicityMentioned in This Episode:
HOPA
Quotes:
“In early-stage renal cancer, no established role exists for adjuvant therapy except in patients with stage 3 renal cell cancer of clear cell histology and high risk for relapse.” — Dr. Lisa Holle
“Bone-modifying agents are recommended for renal cell cancer patients with bone metastases.” — Dr. Lisa Holle
“Early-stage prostate cancer patients have a very high rate of 10-year survival.” — Dr. Lisa Holle
-
HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.
These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.
In this episode of HOPA Now, Dr. Daniel Melzer highlights the top ten clinical pearls regarding various forms and stages of lung cancer and the treatment options for these different disease diagnoses. He also shares chemotherapy treatments and survival rates and other considerations that can help determine future therapy options in various diagnosis situations.
In this episode you will learn:
Lung Cancer Considerations and Treatments
Stage four non-small cell lung cancer targeted therapy guidelines Diagnoses in which treatment must be an immunotherapy plus chemotherapy combination Metastatic disease considerations for first- and second-line setting situations The importance of histology when determining if a patient needs targeted therapy Chemotherapy treatment options and survival rates for stage one, two, and three cancer patients How first-line treatment for small cell lung cancer depends on staging Timing of relapse considerations to help determine future therapy optionsMentioned in This Episode:
HOPA
Tweetables:
“There is a higher overall rate of survival in patients that receive pembrolizumab in the first-line setting.” — Daniel Melzer
“In stage two and stage three patients, there is a survival benefit in receiving chemotherapy versus observation.” — Daniel Melzer
“First-line treatment for small cell lung cancer depends on staging.” — Daniel Melzer
-
Episodes manquant?
-
HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.
These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.
In this episode of HOPA Now, Dr. Allison Baxley covers the high points of the pathology, diagnostic workup, and biology of GI cancers, including colon cancers, exocrine pancreatic cancers, upper GI cancers, gastric cancers, and hepatocellular carcinoma. She covers testing and recommendations, demographics and risk factors, the role of genetics, staging locations, and distinct variations between these various GI cancers.
In this episode, you will learn:
Gastrointestinal Cancers Fundamentals
The basic pathophysiology and common genetic predisposition of colon cancers Recommendations for testing at various stages at colon cancers, including those with metastatic disease BRAF testing and recommendations and common patient response Considerations for diagnostic workup and staging process that may affect treatment decisions during early-stage disease An overview of exocrine pancreatic cancers origination, prognosis, staging decisions and treatment options The role of genetics in pancreatic cancers and recommendations for chemotherapy and PARP inhibitors Upper GI cancers including esophageal, gastric, and esophagogastric junction cancers and their histologics Distinct variations between the geography, demographics and risk factors of adenocarcinomas and squamous cell carcinomas in esophageal cancers Staging locations and clinical trials for EG junction tumors Specific hereditary risk factors for gastric cancer A brief overview of hepatocellular carcinoma including demographics, risk factors, and pathologic typesMentioned in This Episode:
HOPA
Quotes:
“All colon cancer patients should be tested for MSI and MMR status.” — Dr. Allison Baxley
“In patients with early-stage disease, there are several things during the diagnostic workup and staging process that may affect treatment decisions.” — Dr. Allison Baxley
“For gastric cancer specifically, there are several hereditary risk factors that put a patient at higher risk.” — Dr. Allison Baxley
-
HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.
These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.
In this episode of HOPA Now, Dr. Allison Baxley covers some of the most important clinical topics in the treatment of gastrointestinal cancers. She covers treatment recommendations and updates for colorectal cancer, pancreatic cancer, landmark trials in esophageal and gastric cancer, and hepatocellular carcinoma.
In this episode, you will learn:
Gastrointestinal Cancers: Top 10 Clinical Pearls
A review of the landmark MOSAIC clinical trial and its subsequent recommendations An outline of the treatment paradigm of rectal cancer and its chemotherapy, surgery, and radiation treatment options Molecular markers that are relevant in metastatic colon cancer and their effect on the choice of biologic agents Primary tumor location in metastatic colorectal cancer and its influence on certain biologic agents An overview of three landmark studies concerning adjuvant treatment options for pancreatic cancer patients The standard first-line options for metastatic treatment of pancreatic cancer The unique role of pharmacists in the unique supportive care needs of pancreatic cancer patients Landmark trials in esophageal and gastric cancer and drug regimen recommendations An overview of recent findings and recommendations regarding hepatocellular carcinomaMentioned in This Episode:
HOPA
Quotes:
“This trial showed us that certain stage two patients don’t benefit from adjuvant chemotherapy at all.” — Dr. Allison Baxley
“All patients with metastatic colorectal cancer should be tested for K-Ras, N-Ras, and B-Ras status.” — Dr. Allison Baxley
“It’s clear that colon tumors have different molecular characteristics depending on where they arise.” — Dr. Allison Baxley
“Nearly all pancreatic cancer patients also require some degree of pancreatic enzyme replacement due to either their disease or surgery.” — Dr. Allison Baxley
-
HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.
These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.
In this episode of HOPA Now, Dr. Shrina Patel offers an overview of the incessant ovulation theory, biopsy options for diagnosis and treatment, and the progression and timing of HPV to ovarian cancer over time. She also gives an overview of endometrial cancer based on epidemiology, histology, and prognosis, and explains the pathways of serous carcinoma and clear cell carcinoma in the treatment of endometrial cancer.
In this episode, you will learn:
Gynecologic Malignancies Fundamentals
Defining the incessant ovulation theory as a potential cause of sporadic ovarian cancer Understanding how potential mutagenic lesions in DNA are normally encountered and common risk factors of ovarian cancer Biopsy options for diagnosis and fine needle aspiration warnings in treatment of ovarian cancer The progression and timing of HPV associated lesions to ovarian cancer Treatment of and demographics surrounding HPV An overview of endometrial cancer classifications based on epidemiology, histology, and prognosis The pathways of serous carcinoma and clear cell carcinoma in the treatment of endometrial cancerMentioned in This Episode:
HOPA
Quotes:
“The etiology of ovarian cancer is complex and incompletely understood.” — Dr. Shrina Patel
“The progression and timing of HPV associated lesions to ovarian cancer typically happens over ten to twenty years.” — Dr. Shrina Patel
“Type 2 cancers are considered high grade by definition and primarily include serous carcinoma and clear cell carcinoma.” — Dr. Shrina Patel
-
HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.
These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.
In this episode of HOPA Now, Dr. Shrina Patel covers dosage recommendations for ovarian cancer patients and the importance of molecular testing in order to provide treatment and maintenance recommendations and highlights the critical role of pharmacists in ensuring adherence to drug recommendations. She also offers an overview of drug treatments based on various inclusions and exceptions, addresses specific patient treatments, and covers radiation and management of varying acute and chronic toxicities.
In this episode, you will learn:
Gynecologic Malignancies: Top 10 Clinical Pearls
Chemotherapy and dosage recommendations based on different ovarian cancer stages The importance of molecular testing for patients in order to provide treatment and maintenance recommendations The role of pharmacists in ensuring adherence to oral PARP inhibitors How and why the pharmacist needs to define a patient as platinum-resistant, sensitive, or refractory Recommended drugs for patients with recurrent or metastatic cervical cancer An overview of bone metastases and recommended drugs for proper treatment Radiation and management of its associated acute and chronic toxicities Hypertension and handling agent limiting bevacizumab treatments Inclusions and exceptions to treating patients with pembrolizumab and lenvatinib Recommendations for patients with uterine serous carcinomaMentioned in This Episode:
HOPA
Quotes:
“There are no randomized data supporting the use of this regimen in patients with stage 2 disease.” — Dr. Shrina Patel
“Oral chemotherapy has revolutionized oncology, yet with great achievements come challenges.” — Dr. Shrina Patel
“Radiation — with or without chemotherapy — is associated with acute and chronic toxicities.” — Dr. Shrina Patel
-
HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.
These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.
In this episode of HOPA Now, Dr. Christy Harris addresses the main differentiating characteristics of sarcomas from all other cancers, including risk factors and prognosis, focusing mainly on soft tissue sarcomas. She reviews sarcoma identification and considerations, latest breakthroughs and treatments regarding GIST, and offers details for cytotoxic and other targeted treatments.
In this episode, you will learn:
Adult Sarcomas Fundamentals
Differentiating characteristics of sarcomas from most other cancers An overview of the histology and two main categories of sarcomas Identification and percentages of various soft tissue sarcomas Risk factors and prognosis of soft tissue sarcomas Considerations regarding risk factors to remember when reviewing adult sarcomas The correlation between presentation and prognosis of sarcomas and their location Latest breakthroughs and treatments regarding GIST Details for cytotoxic and other targeted chemotherapy treatmentsMentioned in This Episode:
HOPA
Quotes:
“These characteristics described require us to approach this cancer differently than other neoplasms.” — Dr. Christy Harris
“Some sarcomas are technically considered to be benign tumors but have severe comorbidities so must be treated as a malignant tumor.” — Dr. Christy Harris
“Presentation of a sarcoma as well as its prognosis is heavily dependent on where it is located in the body.” — Dr. Christy Harris
-
HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.
These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.
In this episode of HOPA Now, Dr. Christy Harris addresses the top ten clinical pearls regarding adult sarcomas, including an overview of the approval, dosage, and warnings of various drug treatments including doxorubicin, avipritinib, pexidartinib, and tazemetostat. She concludes with recommendations for regimens and collaborations that will produce optimal results for all clinical trials and patients.
In this episode, you will learn:
Adult Sarcomas: Top 10 Clinical Pearls
An overview of the origin and main categories of sarcoma cancers Doxorubicin as the standard treatment option for sarcoma cancers Recommendations for dosage and monitoring of ifosfamide-induced encephalopathy Targets as an area of possible therapeutic benefit in various sarcomas An overview of the newly recognized gastrointestinal stromal tumor (GIST) The role, approval, and warnings associated with the new drugs avipritinib and pexidartinib Understanding epithelioid sarcomas next new therapy — tazemetostat Oral targeted therapies that best demonstrate advancement in the cancer arenaMentioned in This Episode:
HOPA
Quotes:
“Sarcomas are a large, heterogeneous group of cancers that arise from connective tissues such as bone, skeletal and smooth muscle, adipose tissue and cartilage.” — Dr. Christy Harris
“Doxorubicin remains the standard for treatment for most sarcomas. Other agents may be added to it, but doxorubicin remains the workhorse of the sarcoma world.” — Dr. Christy Harris
“Targets have been identified as possible areas of therapeutic benefit for a number of sarcomas.” — Dr. Christy Harris
“Sarcomas are an uncommon tumor for most clinicians to see, but there is an increasing number of oral targeted therapies for individual tumors that demonstrate some advancement in the cancer arena.” — Dr. Christy Harris
-
HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.
These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.
In this episode of HOPA Now, Dr. Samantha Reiss discusses the background and pathophysiology of central nervous system malignancies with a focus on malignant brain tumors and high-grade gliomas. This session covers epidemiology, grading and classification, risk factors, and clinical presentation of central nervous system malignancies. She concludes with an overview of workup and diagnosis information and recommendations for further treatment.
In this episode, you will learn:
Central Nervous System Malignancies Fundamentals
Data surrounding the epidemiology and characterizations of central nervous system malignancies Understanding the WHO classification and grading system through tumor molecular classification Genetic alterations including IDH mutations, 1p19q codeletion, and O-6-methylguanine-DNA-methyltransferase Risk factors and signs and commonly presented symptoms in CNS malignancies An overview of diagnosis, workup, and prognosis information and recommendations for further treatmentMentioned in This Episode:
HOPA
Quotes:
“Central nervous system malignancies are a heterogeneous mix of neoplasms arising from various cells in the CNS.” — Dr. Samantha Reiss
“Primary brain tumors are classified by their histologic similarities based on their cells of origin and classified by their degree of differentiation.” — Dr. Samantha Reiss
“Genetics are only weakly associated with gliomas and there are few rare hereditary syndromes that are associated with increased risk of glioma.” — Dr. Samantha Reiss
-
HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.
These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.
In this episode of HOPA Now, Dr. Samantha Reiss details the standard care for glioblastoma, the most aggressive form of brain tumors. She highlights main considerations surrounding the use of temozolomide, TTFs, and bevacizumab, and touches on the more controversial topics of treating elderly patients and retreatment care options for recurrent glioblastoma. She concludes with an overview of anaplastic gliomas in patients who harbor the 1P19q codeletion and those who don’t.
In this episode you will learn:
Central Nervous System Malignancies: Top 10 Clinical Pearls
Standard of care for glioblastoma, the most aggressive form of brain tumors Considerations when determining if temozolomide is an absolute standard of care for patients with MGMT unmethylated tumors Supportive care for the upfront treatment of glioblastoma and options for PJP prophylaxis The role of the medical device tumor treating fields (TTF) in the upfront treatment of glioblastomas Controversial talking points regarding the treatment of glioblastomas in elderly patients The role of bevacizumab as a treatment of glioblastoma and toxicities to monitor for Recurrent glioblastoma considerations and retreatment care options Goals for the treatment of low-grade gliomas and the role of chemotherapy in this setting Anaplastic gliomas in patients who harbor the 1P19q codeletion and those who don’tMentioned in This Episode:
HOPA
Quotes:
“This trial showed an overall improvement in survival from 12.1 months with radiation alone compared to 14.6 months with radiation plus temozolomide and the survival benefit lasted through the five-year follow-up.” — Dr. Samantha Reiss
“Chemotherapy-induced nausea and vomiting from temozolomide therapy is dose-dependent and standard emetic prophylaxis should be considered for all patients.” — Dr. Samantha Reiss
“The addition of tumor treating fields improved progression free-survival and overall survival in this patient population.” — Dr. Samantha Reiss
“Timing of radiation therapy should be considered to speed the progression and possibility of late neurotoxicity that patients can experience after brain radiation.” — Dr. Samantha Reiss
-
HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.
These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.
In this episode of HOPA Now, Dr. Neelam Patel details the epidemiology, pathophysiology, and staging of breast cancer, one of the most commonly diagnosed cancers in American women. She offers data, diagnosis percentages, and survival rates for breast cancer patients; shares common risk factors, presentation, and common histologies of breast cancer; and details prognostic factors and recent changes to adjuvant treatment guidelines.
In this episode you will learn:
Breast Cancer Fundamentals
Data, diagnosis percentages, and survival rates surrounding breast cancer Common germline mutations in breast cancer patients Risk factors regarding breast cancer, including gender, family history, and estrogen exposure Common presentation of breast cancer masses and common histologies of breast cancer Tumor size, nodal status, and presence of metastatic disease and other prognostic factors including ER/PR and HER2 status and grade of tumors Recent changes to adjuvant treatment guidelinesMentioned in This Episode:
HOPA
Quotes:
“Breast cancer masses usually present as a painless lump that is self-detected or found on screening mammograms.” — Dr. Neelam Patel
“In recent years the AJCC updated their guidelines to include other prognostic factors such as ER/PR and HER2 status and grade of the tumor.” — Dr. Neelam Patel
“One thing to remember is this is a prognostic stage and is more to help the clinician and patient understand what their prognosis is, and does not necessarily dictate treatment.”
— Dr. Neelam Patel -
HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.
These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.
In this episode of HOPA Now, Dr. Neelam Patel highlights various drug regimens and recommendations including adjuvant Anti-HER2 therapy, PIK3CA, characteristics of CDK4/6 inhibitors, and considerations for adjuvant chemotherapy. She details the key role that pharmacists can play in helping manage potential toxicities and ends with recommendations on when to stop therapy and how to employ supported care.
In this episode you will learn:
Breast Cancer Top 10 Clinical Pearls
Utilizing adjuvant Anti-HER2 therapy based on residual disease versus no residual disease The relationship between PIK3CA and the place of Alpelisib in therapy Mechanical characteristics of CDK4/6 inhibitors, dosing recommendations, recent changes, and its place in therapy NCCN guidelines for using endocrine therapy versus cytotoxic therapy in metastatic breast cancer Adjuvant chemotherapy for hormone receptor-positive HER2-negative disease and findings of the TAILORx study PARP inhibitors used in treating breast cancers and adjuvant Capecitabine Bone modifying therapy and drug dosing recommendations The evaluation of metastatic disease, when to stop therapy, and supported careMentioned in This Episode:
HOPA
Tweetables:
“Ado-trastuzumab emtansine is recommended in the adjuvant setting if patients have residual disease following neoadjuvant HER2 targeted therapy.” — Dr. Neelam Patel
“Close monitoring and management is one of the key roles that we can play as pharmacists in helping manage these toxicities.” — Dr. Neelam Patel
“If a patient is symptomatic and requires quick disease control, cytotoxic chemotherapy may be recommended.” — Dr. Neelam Patel
“In general, chemotherapy is chosen based on patient-specific risk factors.” — Dr. Neelam Patel
-
HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.
These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.
In this episode of HOPA Now, Dr. Lisa Holle offers an overview of genitourinary cancers, including bladder, kidney, and testicular cancers, their causes and risk factors, appropriate treatment options, and standard survival rates.
In this episode you will learn:
Genitourinary Cancers Fundamentals
Key differences between the anatomy and pathophysiology of muscle and non-muscle invasive bladder cancers Survival rates of bladder cancer patients Various types of kidney cancers and their appropriate treatments The cause of early-stage prostate cancer and the inhibitors of normal growth of the prostate Possible mechanisms of early-stage prostate cancer Understanding testicular cancers as germ cell tumors, their subcategories, and common risk factorsMentioned in This Episode:
HOPA
Quotes:
“Understanding the pathophysiology of bladder cancer relies on the understanding of the anatomy of the bladder.” — Dr. Lisa Holle
“The treatments for clear cell carcinoma are focused on targeting the pathways that are affected.” — Dr. Lisa Holle
“Most testicular cancers are histologically categorized as germ cell tumors.” — Dr. Lisa Holle
-
HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.
These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.
In this episode of HOPA Now, Dr. Bernard Marini reviews key background information on acute leukemias and MDS. He covers the key mutations, common abnormalities, characteristics, and outcomes of both AML and ALL, and offers diagnosis requirements, exceptions, and guidelines regarding various treatment options.
In this episode you will learn:
Adult Acute Leukemias & Myelodysplastic Syndrome Fundamentals
MDS median age at diagnosis, common risk factors including exposure to radiation and unbalanced chromosomal changes, and the prognostic scoring system Secondary AML characteristics and considerations AML diagnosis requirements, exceptions, and NCCN guidelines regarding ELN risk stratification FLT-3’s role as both an important predictive and prognostic biomarker Characteristics and outcomes of ALL as both a pediatric and adult malignancy Common abnormalities of ALL, including the presence or absence of the Philadelphia chromosome Understanding IKZF13 as a critical regulator of lymphoid differentiation Alternate methods and recommendations for testing measurable residual diseaseMentioned in This Episode:
HOPA
Quotes:
“For the diagnosis of AML, more than 20% blasts are required unless certain cytogenetic abnormalities are present.” — Dr. Bernard Marini
“FLT-3 is an important predictive and prognostic biomarker.” — Dr. Bernard Marini
“We typically think of ALL as a pediatric malignancy, however, 40-45% of all cases occur in adult patients.” — Dr. Bernard Marini
“MRD at almost every time point is prognostic for relapse in overall survival in ALL.”
— Dr. Bernard Marini -
HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.
These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.
In this episode of HOPA Now, Dr. Bernard Marini highlights the main clinical pearls of adult acute leukemias and myelodysplastic syndrome, including unique factors that affect dosing, drug monitoring factors, and guidelines, and the oncologic stewardship and dosing caps for various drug usage.
In this episode you will learn:
Adult Acute Leukemias & Myelodysplastic Syndrome: Top 10 Clinical Pearls
There are unique lenalidomide sensitivities for patients with deletion 5q. Thrombopoietin mimetics and growth factors for patients with MDS Guidelines for use of potent ASAL antifungals Denosumab azomycin and oncologic stewardship and dosing caps Secondary AML and oncologic stewardship outcomes and alternatives Characteristics and management of IDH inhibitors and differentiation syndrome Asparaginase and therapeutic drug monitoring and a comparison of adult versus pediatric patients reactions and survival rates Blinatumomab and inotuzumab use and outcomes in patients with less disease burden Balancing safety and efficacy of TKIs in patients with ph positive ALLMentioned in This Episode:
HOPA
Quotes:
“Patients with deletion 5q are uniquely sensitive to lenalidomide.” — Dr. Bernard Marini
“Given the flaws in the alpha trial and the meta-analysis, this is potentially a place for oncologic stewardship in avoidance in risk in a drug with no overall survival benefit.” — Dr. Bernard Marini
“IDH inhibitors in AML are fascinating agents.” — Dr. Bernard Marini
“Adults and young adult patients have significantly worse survival rates compared to pediatric ALL counterparts.” — Dr. Bernard Marini
-
HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.
These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.
In this episode of HOPA Now, Brian Doe details the background and pathophysiology of lymphoma, how to differentiate T-cell lymphomas, and the aggressive nature of all the lymphomas. He highlights the characteristics and symptoms of various forms of lymphoma and makes recommendations for treatments based on pathological and cellular findings.
In this episode you will learn:
Lymphomas Fundamentals
Lymphoma presentation and pathophysiology Hallmark signs and common symptoms of lymphoma Varying characteristics of Hodgkins and non-Hodgkin’s lymphomas Characteristics and risks of indolent lymphomas including follicular lymphoma, B-cell lymphoma, and mantle cell lymphoma T-cell lymphomas, symptoms, and the effect they have on organs Goals of therapy and the effects of peripheral T-cell lymphomaMentioned in This Episode:
HOPA
Quotes:
“Hodgkin’s lymphomas, in general, have good prognosis and are considered curable with standard chemotherapy such as ABVD.” — Brian Doe
“Non-Hodgkin’s lymphomas are more responsive to chemotherapy and may be curable despite its aggressive nature.” — Brian Doe
“Controversy exists in how grade 3 follicular lymphoma should be treated as it mimics a more aggressive disease course and carries a risk of transformation to diffuse large B-cell lymphoma.” — Brian Doe
-
HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.
In this episode of HOPA Now, Nelly Adel, PharmD, BCOP, BCPS and Deanna Argentieri, PharmD, aim to identify the basic requirements to have students on an oncology APPE site, illustrate the various structures for APPE rotations, set expectations for students versus residents on same rotation, highlight the requirements for delivering and providing timely and appropriate feedback to enhance student performance in an oncology setting with a focus in the ambulatory setting, and demonstrate the essential roles of an oncology pharmacist career in Oncology.
This podcast is part of a General Pharmacy Education Self-Paced Study Module in HOPA Learn. To view the full course and claim credit, please visit HOPA Learn and register for the course.
In this episode, you will learn:
Guidelines for establishing an oncology site
Determine the affiliations established between the site where you are practicing and the school of pharmacy. Considerations include student access to a computer, distance from the university, access to EMRs, and the duration of the rotation. Qualifications of preceptors and student interest in oncology Article information outlining the process and guidelines Creighton University pharmacists and faculty used to establish an oncology elective Understand the specific school curriculum and guidelines for APPE. Identify prior student experiences and rotations to determine interest.Setting expectations for students in their rotations
Communication, interest, and a clearly-defined plan is a critical step to understanding what the student is hoping to get out of the rotation. Investing time in students will ensure that you have their best interests in mind. Recommendations for syllabus details that will clearly outline your expectations. Taking on students is a time commitment from everyone, but setting expectations will result in a greater payoff in the end.Handling students vs. residents
Many practice sites have students and residents — be sure to delineate between student and resident expectations. The benefits of providing layered learning as an effective way to integrate multiple learners into a practice setting. Clearly define the goals and objectives of the rotation, preceptor, and learner. Students and residents need to have clear and distinct differences between their objectives and expectations, including in their rubrics. Students and residents should NOT have access to the same information based on their differing levels of verification.Feedback for students vs. residents
Feedback is crucial in learner growth and essential to help students develop the necessary clinical skills for practice. Feedback should be the backbone of the learning experience. Feedback can be formal or informal but should be done regularly to assess performance and set future goals and expectations. Ongoing feedback helps to encourage interest and motivation and has been linked to satisfaction of the preceptor. Feedback allows for self-reflection and the ability to assess their impact on the team/service. Ideas for giving effective feedback that is descriptive, adapted to the situation at hand, succinct, and include first-hand knowledge Ineffective feedback that should be avoided in all situationsRole Model — Careers in Oncology
Role modeling is one of the crucial roles of a preceptor as it demonstrates the skills that a pharmacist performs in a given time as well as shows to the student how they can practice in the future. Precepting can give students various insights on how an oncology pharmacist can practice in any setting, including inpatient and outpatient settings. Roles can extend to hospital satellites, a clinical specialist, a manager, a coordinator, a faculty, and more. A variety of options for practice can vary among several hospital systems.Mentioned in This Episode:
HOPA
Literature for this Episode:
Nystrom KK, Pick AM. An oncology pharmacy practice elective course for third-year pharmacy students. Am J Pharm Educ. 2013; 77(1) Article 12.
Bates JS, Buie LW. A study of layered learning in oncology. Am J Pharm Educ. 2016; 80(4) Article 68.
Hall A, Miguel A, Weitzel K. Providing feedback to learners in outpatient and ambulatory care practice settings Curr Pharm Teach Learn. 2015; 7:348-356
Quotes:
“There are many opportunities to teach a student on rotation, not only about the oncology topics but insights into future career options.” — Nelly Adel
“Investing time in students from the beginning of their practice experience really helps to establish that trust and assurance that you have their best interests in mind.”
— Deanna Argentieri“Keep in mind that the senior preceptor is the major driver of pharmacy services.”
— Deanna Argentieri“For preceptors, it’s important to note that when discussing topics or patient presentations there is a variation between what a resident can see versus a student.” — Nelly Adel
“Feedback should be the backbone of the student’s learning experience. It should be informal, given regularly, and in a timely manner.” — Deanna Argentieri
-
HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.
These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.
In this episode of HOPA Now, Brian Doe offers an overview of the fundamentals of lymphomas, including biopsy recommendations, histological determinations, and screenings that are commonly administered during treatment. He highlights the indicators for starting follicular lymphoma treatment and shares guidelines and criteria for administering high dose methotrexate, and concludes with information regarding various B-cell lymphomas and mycosis fungoides.
In this episode you will learn:
Lymphomas: Top 10 Clinical Pearls
Biopsy recommendations for making an accurate diagnosis Ensure necessary workup is completed and considered prior to initiating treatment Proper management and prevention of Hepatitis B reactivation Understanding Rituximab and the biosimilars and NCCN recommendations Indications for starting follicular lymphoma treatment Prevention of toxicities in HD methotrexate and indicators for alternate treatment options Dose-adjusted R-EPOCH treatment guidelines and criteria Prevention of bacterial and other infections CNS prophylaxis for patients with diffuse large B-cell lymphoma Maximizing patient care for patients with various B-cell lymphomas and mycosis fungoidesMentioned in This Episode:
HOPA
Quotes:
“It is important to delay the use of corticosteroids until obtaining the biopsy when possible as lymphomas are sensitive to steroids and specimens may be affected.” — Brian Doe
“If Hepatitis B surface antigen or core antibody screening is positive, a consultation to a gastroenterologist or infectious disease expert is recommended.” — Brian Doe
“When we think about late-stage disease, we sometimes immediately jump to consider treatment, however not all patients benefit and may be better managed with the watchful waiting approach to minimize treatment-related toxicities.” — Brian Doe
-
HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.
These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.
In this episode of HOPA Now, Dr. Kirollos Hanna highlights the fundamentals regarding multiple myeloma, the 14th most common cancer in the U.S. He offers details regarding diagnosis data and risk factors, the pathophysiology and molecular biology of multiple myeloma, the tools used to stage select patients and the importance of patient adherence to varying degrees of therapy regimens.
In this episode you will learn:
Multiple Myeloma: Fundamentals
Diagnosis data and figures surrounding multiple myeloma Risk factors for developing multiple myeloma The main differentiating factors for MGUS smoldering and active myeloma Pathophysiology and disease-related symptoms of multiple myeloma C.R.A.B. symptoms, their causes, and common resulting effects Molecular biology of myeloma and cytogenetic abnormality prognostic factors High-risk differentiating factors and the tools used to stage select patients The importance of patient adherence to therapy regimensMentioned in This Episode:
HOPA
Quotes:
“We know that cytogenetic abnormalities oftentimes have a lot to do with preventing normal differentiation of apoptosis.” — Dr. Kirollos Hanna
“It is very rare or uncommon to see patients have IGM or IGD myeloma, and extremely rare to see patients not have any M proteins present in the blood or the urine.” — Dr. Kirollos Hanna
“Response criteria ranges anywhere from stringent and complete response all the way to progressive or refractory disease.” — Dr. Kirollos Hanna
-
HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.
These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.
In this episode of HOPA Now, Dr. Kirollos Hanna details the top ten clinical pearls for managing patients with multiple myeloma. Topics include the goals of therapy, the proper approach to treatment and transplant options, details of inhibitors and administration guidelines, the role of the pharmacist in managing complex regimens, and more.
In this episode you will learn:
Multiple Myeloma: Top 10 Clinical Pearls
The goals of therapy regarding the disease state of multiple myeloma C.R.A.B. symptoms as the hallmark representation of multiple myeloma patients The approach to treatment and transplant options is based on various patient factors. The efficacy and complexities of triplet therapies Details of the three main proteasome inhibitors, administration guidelines, and common adverse reactions Approved immuno module drugs and their associated increased patient risk factors Highlighting the role of the pharmacist in managing complex regimens Novel upcoming mechanisms for managing multiple myeloma patientsMentioned in This Episode:
HOPA
Quotes:
“It’s important to note that multiple myeloma remains, to date, an incurable disease.”
— Dr. Kirollos Hanna“Proteasome inhibitors are indicated in numerous frontline and relapse refractory regimens in multiple myeloma, regardless of transplant eligibility.” — Dr. Kirollos Hanna
“Pharmacists really play an integral role in managing these patients.” — Dr. Kirollos Hanna
“It’s likely that we will see some of these therapies come to light within the next several years for the multiple myeloma patient population.” — Dr. Kirollos Hanna
- Montre plus
![[Education] Genitourinary Cancers: Top 10 Clinical Pearls](https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/36/86/1b/36861b5b-0638-8df5-2451-97bb5eb2c461/mza_12354986147563141.png/80x80bb.jpg)